Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy

[1]  N R Schneider,et al.  Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Behm,et al.  Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study , 1990 .

[3]  Jonathan J. Shuster,et al.  Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study , 1990 .

[4]  M. Borowitz,et al.  Prognostic importance of the pre-B-cell immunophenotype and other presenting features in B-lineage childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1989, Blood.

[5]  H. Jürgens,et al.  Rapidly rotating combination chemotherapy in childhood acute lymphoblastic leukemia: preliminary results of a randomized comparison with conventional treatment. , 1988, Leukemia.

[6]  A. Look,et al.  The cytogenetics of childhood leukemia: clinical and biologic implications. , 1988, Pediatric clinics of North America.

[7]  A. Look,et al.  Teniposide plus cytarabine improves outcome in childhood acute lymphoblastic leukemia presenting with a leukocyte count greater than or equal to 100 x 10(9)/L. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Pastan,et al.  Multiple-drug resistance in human cancer. , 1987, The New England journal of medicine.

[9]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[10]  D. Williams,et al.  A direct bone marrow chromosome technique for acute lymphoblastic leukemia. , 1984, Cancer genetics and cytogenetics.

[11]  Goldie Jh,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982 .

[12]  A. Goldin,et al.  The chemotherapy of human and animal acute leukemia. , 1971, Cancer chemotherapy reports.

[13]  R. H. Levin,et al.  The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. , 1965, Blood.

[14]  J. Shuster,et al.  Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1990, Blood.

[15]  S. Lipshultz,et al.  Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. , 1990, The Journal of pediatrics.

[16]  G. Henze,et al.  Results and significance of six randomized trials in four consecutive ALL-BFM studies. , 1990, Haematology and blood transfusion.

[17]  A. Cork,et al.  Molecular heterogeneity in acute leukemia lineage switch. , 1989, Blood.

[18]  F. Behm,et al.  Correlation of karyotype and immunophenotype in childhood acute lymphoblastic leukemia. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Pui,et al.  High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St. Jude Total Therapy Study X. , 1988, Medical and pediatric oncology.

[20]  Cyclophosphamide and bone marrow transplantation. , 1988, The New England journal of medicine.

[21]  C. Pui,et al.  Limiting toxicities during intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. , 1987, Haematology and blood transfusion.

[22]  Improvement in treatment for children with acute lymphoblastic leukaemia , 1986, Indian journal of pediatrics.

[23]  C. Pui,et al.  Early results of intensified remission induction chemotherapy for childhood acute lymphocytic leukemia. , 1986, Medical and pediatric oncology.

[24]  J. Pullen,et al.  Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. , 1986, Medical and pediatric oncology.

[25]  H. Sather.  Age at diagnosis in childhood acute lymphoblastic leukemia. , 1986, Medical and pediatric oncology.

[26]  G. Rivera,et al.  Variation by race in presenting clinical and biologic features of childhood acute lymphoblastic leukaemia: implications for treatment outcome. , 1985, Leukemia research.

[27]  H. Klinger,et al.  ISCN 1985 : an international system for human cytogenetic nomenclature (1985) : report of the Standing Committee on Human Cytogenetic Nomenclature , 1985 .

[28]  M. Seip,et al.  Intermediate dose methotrexate in childhood acute lymphocytic leukemia , 1984 .

[29]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.

[30]  A. Bleyer.  Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. , 1977, Cancer treatment reports.